Company profile for Kyowa Hakko Bio

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

Kyowa Hakko Bio is a Japanese leading company of bio-technology and fermentation. We are utilizing the world's top-level fermentation and synthesis technologies to supply domestic and overseas users with various fine chemical products centered on amino and nucleic acids for pharmaceuticals, nutritional supplements, and industrial use, as well as the derivatives of such acids. Through the rapid progress in genome analysis see...
Kyowa Hakko Bio is a Japanese leading company of bio-technology and fermentation. We are utilizing the world's top-level fermentation and synthesis technologies to supply domestic and overseas users with various fine chemical products centered on amino and nucleic acids for pharmaceuticals, nutritional supplements, and industrial use, as well as the derivatives of such acids. Through the rapid progress in genome analysis seen in recent years, we anticipate the development of new biotechnology processes and products from fermentation, a technology which humankind has been utilizing since time immemorial.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
Japan
Address
Address
Ohtemachi Building, 1-6-1,Ohtemachi,Chiyoda-ku, Tokyo, 100-8185, Japan
Telephone
Telephone
Linkedin
Linkedin
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

CPhI South East Asia

Not Confirmed

envelop Contact Supplier

CPhI South East Asia

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

INTERVIEW #SpeakPharma

[Sponsored by another company]
Alchem NicSelect™ grants customers royalty-free access to T-MAX™ tech for 3-in-1 vape satisfaction in flavour-restricted markets
With increasing flavour bans in key markets, vaping brands are facing significant challenges in providing satisfying alternatives to vapers and smokers looking to transition. Recognising this need, Alchem NicSelect™ is making a bold move by offering its key customers royalty-free and unrestricted geographical access to its revolutionary T-MAX™ technology.“At Alchem NicSelect™, we understand the urgency for vaping brands to adapt to new regulations without compromising on satisfaction. By offering royalty-free access to T-MAX™ technology, we empower our customers to provide the closest cigarette-like experience possible, even in markets with strict flavour restrictions,” said Riccardo Santambrogio, Europe Sales Manager.HIGHLIGHTS// offering royalty-free access to T-MAX™ technology/ unrestricted geographical access/ closest cigarette-like experience Addressing the biggest barrier: Nicotine satisfactionOne of the primary reasons many vapers are dissatisfied and smokers struggle to switch to vaping is that traditional nicotine solutions fail to replicate the rapid satisfaction provided by cigarettes. Nicotine replacement therapies (NRTs) and even conventional vaping products often lack the immediate nicotine hit, throat feel, and overall experience that smokers are accustomed to. T-MAX™ solves this problem by engineering a nicotine experience that closely mimics cigarette consumption without relying on flavours.T-MAX™ provides a unique 3-in-1 approach:1. The Speed of a Cigarette – Rapid nicotine delivery and rush within seconds for immediate satisfaction.2. The Power of Nicotine Salts – A stronger perceived nicotine effect without exceeding legal limits (20 mg/ml nicotine limit under the European Tobacco Products Directive). With T-MAX™, 8 mg/ml feels like 20 mg/ml, and 14 mg/ml feels like 40 mg/ml.3. The Throat Hit of Freebase Nicotine – Especially in a flavour-free formulation, the combined ingredients in T-MAX™ deliver an even more satisfying throat feel than expected from nicotine base, much closer to and more familiar with a cigarette throat feel that habitual smokers recognise.HIGHLIGHTS// unique 3-in-1 approach/ rush within seconds/ stronger perceived nicotine effect without exceeding legal limits/ more satisfying throat feel that habitual smokers recogniseNo flavour, but not less satisfyingWhile flavours have traditionally played a role in vaping adoption, market realities are shifting. With flavour bans spreading across regions, brands need solutions that deliver satisfaction without relying on taste. Consumer research has shown that T-MAX™ performs exceptionally well even without added flavours. Since most cigarette smokers do not smoke for the tobacco flavour but rather for the nicotine hit and habitual experience, T-MAX™ provides a viable alternative that aligns with new regulatory landscapes.HIGHLIGHTS// flavour bans spreading across regions/ T-MAX™ performs exceptionally well even without added flavoursEmpowering vape brands with free access to T-MAX™By granting customers royalty-free access to the T-MAX™ technology, Alchem NicSelect™ is removing barriers for vaping brands and original equipment manufacturers (OEMs) looking to adapt to regulatory changes. This open-access approach ensures that manufacturers can integrate T-MAX™ into their product lines without additional costs, allowing them to offer superior nicotine satisfaction in markets where flavours are no longer an option.HIGHLIGHTS// removing barriers for vaping brands and OEMs looking to adapt/ manufacturers can integrate T-MAX™ into product lines without additional costsThe future of vaping in restricted marketsWith T-MAX™, the vaping industry has a powerful tool to retain customers and convert smokers who have struggled with traditional vaping products. By delivering the key elements of cigarette satisfaction — without combustion or flavours — T-MAX™ is set to redefine what a satisfying vape experience means in a post-flavour-ban world.“Our commitment to innovation and accessibility means we are providing our customers with the solutions they need to navigate an evolving regulatory landscape. T-MAX™ allows brands to offer a highly satisfying experience that mimics smoking without relying on flavours. The message is clear: no flavour, but not less satisfying”, added Santambrogio.HIGHLIGHTS// powerful tool to retain customers and convert smokers/ delivering the key elements of cigarette satisfaction without combustion or flavours/ no flavour, but not less satisfying

Impressions: 1235

https://www.pharmacompass.com/speak-pharma/alchem-nicselect-grants-customers-royalty-free-access-to-t-max-tech-for-3-in-1-vape-satisfaction-in-flavour-restricted-markets

Radio Compass
06 May 2025

VLOG #PharmaReel

[Sponsored by another company]
This PharmaReel showcases Allsino Pharmaceutical, a company that provides GMP-certified RSMs and APIs to global pharma companies, specializing in peptides, oligonucleotides, and small molecule CDMO services. Allsino has a presence in the US, EU, China and Japan.

Impressions: 1215

read-more

DATA COMPILATION #PharmaFlow

[Sponsored by another company]
J&J’s Intra‑Cellular buyout, BMS’ oncology gambit, Sanofi’s Blueprint acquisition drive mega deals in H1 2025
The pharmaceutical industry has witnessed a wave of mergers, acquisitions, and strategic partnerships so far in the first half (H1) of 2025, with deal values exceeding US$ 170 billion.PharmaCompass’ data shows oncology alone accounted for nearly US$ 47 billion in deal value, followed by US$ 18 billion each in immunology and psychiatry, US$ 17 billion in nutrition/weight loss and US$ 7 billion in neurology.Pharma majors such as Johnson & Johnson and Bristol Myers Squibb led with two deals worth over US$ 10 billion each. Sanofi executed a series of deals in the immunology and neuro-inflammation space. And Eli Lilly stood out for its aggressive dealmaking, which spanned oncology, pain, RNA therapies, and AI-driven oligonucleotides. In all, it signed seven deals worth over US$ 1 billion each. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available)H1 records several mega deals as J&J buys Intra-Cellular, BMS ties up with BioNTech, Sanofi acquires BlueprintJohnson & Johnson dominated headlines with its US$ 14.6 billion acquisition of Intra-Cellular Therapies in January 2025. This marks the largest biopharma deal since Novo Nordisk’s US$ 16.5 billion acquisition of Catalent in February 2024. This acquisition positions J&J as a formidable player in the neuroscience space. Bristol Myers Squibb entered into a US$ 11.1 billion partnership with BioNTech. The deal structure — US$ 3.5 billion in unconditional payments and up to US$ 7.6 billion in milestone payments — demonstrates BMS’ confidence in BNT327, a next-generation bispecific antibody in phase 3 trials for treating extensive stage small cell lung cancer and non-small cell lung cancer.Sanofi acquired Blueprint Medicines for US$ 9.5 billion in order to enhance its rare disease portfolio. The French drugmaker is also creating a comprehensive immunology portfolio. The company signed a US$ 1.9 billion deal for Dren Bio’s DR-0201 bispecific antibody for autoimmune diseases. Sanofi also acquired Vigil Neuroscience for US$ 470 million for its phase 2-ready Alzheimer’s disease candidate. Additionally, the drugmaker secured a US$ 1.84 billion global license agreement with Earendil Labs for two next-generation bispecific antibodies.Pfizer’s US$ 6.05 billion partnership with 3SBio provides it global licensing rights (excluding China) for SSGJ-707, a bispecific antibody currently undergoing multiple clinical trials in China for non-small cell lung cancer, metastatic colorectal cancer, and gynecological tumors. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Obesity gold rush sees Roche, AbbVie, Sciwind ink deals; Novo pledges over US$ 5 bn across three dealsThe obesity therapeutics market has triggered intense competition among pharmaceutical giants. Roche’s US$ 5.3 billion partnership with Zealand Pharma is focused on petrelintide, an amylin analog designed to preserve lean mass better than existing GLP-1-based treatments. The collaboration combines petrelintide with Roche’s dual GLP-1/GIP receptor agonist CT-388, creating a differentiated obesity treatment.Market leader Novo Nordisk has promised over US$ 5 billion across three major obesity deals in 2025. The US$ 2.2 billion Septerna collaboration targets oral small molecule medicines for obesity and cardiometabolic diseases.Novo signed a separate US$ 2 billion agreement with China’s United Biotechnology for UBT251, a triple agonist for GLP-1, GIP, and glucagon receptors in phase 2 clinical development for obesity, type 2 diabetes, and other diseases. The company’s third major deal, a US$ 1 billion partnership with Lexicon Pharmaceuticals, provides it access to LX9851, a molecule in preclinical development for obesity and associated metabolic disorders.Sciwind Biosciences secured a US$ 2.5 billion global licensing and collaboration agreement with Verdiva Bio Limited for the global development and commercialization of a portfolio of metabolic diseases therapies. AbbVie entered the amylin arena through its US$ 2.2 billion Gubra partnership for GUB014295, a candidate in phase 1 trials for treating obesity. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Molecular glue degraders draw investments; Lilly signs seven deals over US$ 1 billion eachMolecular glue degraders have emerged as a transformative therapeutic modality, attracting significant investment across multiple partnerships. AbbVie’s US$ 1.64 billion collaboration with Neomorph leverages the biotech’s leading molecular glue discovery platform for oncology and immunology applications.Genentech’s potential US$ 2.1 billion partnership with Orionis Biosciences focuses on small-molecule monovalent glue medicines for novel and challenging oncology targets. This is the second partnership between the two companies, following their initial 2023 collaboration.Eli Lilly has collaborated with Magnet Biomedicine, utilizing Magnet’s TrueGlue discovery platform for oncology applications. The deal could be worth up to US$ 1.3 billion.Eli Lilly has emerged as one of 2025’s most active dealmakers, with approximately seven deals exceeding US$ 1 billion each. The company’s US$ 2.5 billion Scorpion Therapeutics acquisition provides access to STX-478, an experimental oral therapy in early-stage trials for breast cancer and advanced solid tumors, potentially addressing 30 to 40 percent of hormone-positive breast cancer patients.On June 17, Lilly announced the acquisition of gene-editing startup Verve Therapeutics for US$ 1.3 billion. Lilly’s US$ 1 billion SiteOne acquisition announced in May brings STC-004, a phase 2-ready non-opioid chronic pain treatment to its pipeline. Other partnerships announced by Lilly include a US$ 1.4 billion capsid licensing deal with Sangamo for central nervous system disease genomic medicines and a US$ 1.3 billion collaboration with South Korean company Rznomics for RNA-based hearing loss treatments. Lilly has also strengthened its oligonucleotide pipeline through a potential US$ 1 billion collaboration with Creyon Bio for AI-designed oligonucleotide therapies targeting RNA. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Merck KGaA acquires SpringWorks for US$ 3.9 bn; Novartis buys out Anthos for US$ 3.1 bnAstraZeneca signed a US$ 5.3 billion AI-led research agreement with China’s CSPC Pharmaceuticals Group to advance the discovery of novel oral candidates for immunological diseases. Merck KGaA acquired SpringWorks for US$ 3.9 billion in April, which gave it access to two FDA-approved therapies — Ogsiveo (nirogacestat), the first and only approved therapy for adult patients with progressing desmoid tumors requiring systemic treatment, and Gomekli (mirdametinib), the first and only FDA-approved therapy for adults and children with neurofibromatosis type 1-associated plexiform neurofibromas.Novartis’ US$ 3.1 billion Anthos Therapeutics acquisition centered around abelacimab, a potential first-in-class monoclonal antibody currently in three phase 3 studies for stroke and systemic embolism prevention in atrial fibrillation patients.GSK’s US$ 2 billion acquisition of Boston Pharmaceuticals’ efimosfermin targets steatotic liver disease (fatty liver disease). The medicine is also in clinical development for MASH treatment. GSK’s second major deal involved the US$ 1.15 billion acquisition of US biotech IDRx, strengthening its gastrointestinal cancer portfolio.The pharma industry also drew some private equity interest as Bain Capital acquired Japan’s Mitsubishi Tanabe Pharma from Mitsubishi Chemical Group for US$ 3.3 billion. View Pharma & Biotech Acquisitions, Deals & Agreements in 2025 as of June 14 (Free Excel Available) Our viewDespite an uncertain geopolitical environment, the year has seen a surge in M&As and dealmaking in the first half of 2025. However, a sizable chunk of the acquisitions were bolt-on transactions, indicating that companies are not ready to take on risks, and are buying out smaller players who strategically fit into their operations. Going forward, there are indications that M&A activity will stay strong throughout 2025. 

Impressions: 2783

https://www.pharmacompass.com/radio-compass-blog/j-j-s-intra-cellular-buyout-bms-oncology-gambit-sanofi-s-blueprint-acquisition-drive-mega-deals-in-h1-2025

#PharmaFlow by PHARMACOMPASS
19 Jun 2025

NEWS #PharmaBuzz

read-more
read-more

https://www.pharmacompass.com/pdf/news/kyowa-hakko-bio-co-ltd-on-health-canada-inspection-list-9449.pdf

HEALTH CANADA
17 Apr 2023

https://www.prnewswire.com/news-releases/kyowa-hakko-acclaimed-by-frost--sullivan-for-its-non-gmo-allergen-free-immune-support-paraprobiotic-ingredient-immuse-301379881.html

PRNEWSWIRE
21 Sep 2021

https://www.prnewswire.com/news-releases/mei-pharma-and-kyowa-kirin-announce-first-patient-with-marginal-zone-lymphoma-dosed-in-expanded-global-phase-2-tidal-study-evaluating-zandelisib-301306621.html

PRNEWSWIRE
07 Jun 2021
Japan's Kyowa Kirin reorganizes quality responsibilities
Japan's Kyowa Kirin reorganizes quality responsibilities

26 Nov 2019

// Eric Palmer FIERCE PHARMA

https://www.fiercepharma.com/manufacturing/japan-s-kyowa-kirin-reorganizes-quality-responsibilities

Eric Palmer FIERCE PHARMA
26 Nov 2019

https://www.pharmacompass.com/pdf/news/kyowa-hakko-bio-on-health-canada-inspection-list-1542450249.pdf

HEALTH CANADA
17 Nov 2018

https://www.reuters.com/article/us-abbvie-biosimilars/eu-approves-fifth-copy-of-abbvies-18-billion-drug-humira-idUSKCN1M011N

Ben Hirschler REUTERS
21 Sep 2018

Excipients

Click here to find the perfect excipient manufacturers by their capabilities

Inspections and registrations

Upload your audits for free, ask us

ABOUT THIS PAGE

Contact Kyowa Hakko Bio and get a quotation

Kyowa Hakko Bio is a supplier offers 73 products (APIs, Excipients or Intermediates).

Find a price of Glutathione bulk with DMF, CEP, JDMF offered by Kyowa Hakko Bio

Find a price of Isoleucine bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of L-Alanine API bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of L-Arginine Hydrochloride API bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of L-Leucine API bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of Tryptophan bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of L-Histidine bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of L-Threonine bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of Lysine Acetate bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of Lysine Hydrochloride bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of Phenylalanine bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of Pravastatin bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Proline bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of Serine bulk with CEP, JDMF offered by Kyowa Hakko Bio

Find a price of Aspartic Acid API bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Citicoline Sodium bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Glycine bulk with JDMF offered by Kyowa Hakko Bio

Find a price of L-Glutamine bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Acetylpyridine Adenine Dinucleotide bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Adenine bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Adenosine 5'-Monophosphate bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Aluminium Hydroxide bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Amino Acids Mixture bulk with DMF offered by Kyowa Hakko Bio

Find a price of Calcium Aspartate bulk with JDMF offered by Kyowa Hakko Bio

Find a price of CCRIS 3941 bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Dibasic Calcium Phosphate Dihydrate bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Dl-Histidine Monohydrochloride Monohydrate bulk with JDMF offered by Kyowa Hakko Bio

Find a price of DL-Valine API bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Glutathione bulk offered by Kyowa Hakko Bio

Find a price of L-Arginine bulk with JDMF offered by Kyowa Hakko Bio

Find a price of L-Arginine Hydrochloride API bulk with CEP offered by Kyowa Hakko Bio

Find a price of L-Histidine bulk with CEP offered by Kyowa Hakko Bio

Find a price of L-Threonine bulk with JDMF offered by Kyowa Hakko Bio

Find a price of L-VALINE bulk with CEP offered by Kyowa Hakko Bio

Find a price of Magnesium Carbonate bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Magnesium Oxide bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Proline bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Serine bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Silicic Acid (H6Si2O7), Aluminum Salt (1:2) bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Sanarumin bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Kyowa Suimagu bulk with JDMF offered by Kyowa Hakko Bio

Find a price of Oxyglutathione Kyowa bulk with JDMF offered by Kyowa Hakko Bio

Find a price of 7-Cyanoquinocarcinol bulk offered by Kyowa Hakko Bio

Find a price of Acadesine bulk offered by Kyowa Hakko Bio

Find a price of Aceglutamide bulk offered by Kyowa Hakko Bio

Find a price of Aceglutamide Aluminium bulk offered by Kyowa Hakko Bio

Find a price of Adenosine bulk offered by Kyowa Hakko Bio

Find a price of Amino Acids Mixture bulk offered by Kyowa Hakko Bio

Find a price of Bucillamine bulk offered by Kyowa Hakko Bio

Find a price of Chembl2106438 bulk offered by Kyowa Hakko Bio

Find a price of D-Serine API bulk offered by Kyowa Hakko Bio

Find a price of Dacarbazine bulk offered by Kyowa Hakko Bio

Find a price of Dopamine bulk offered by Kyowa Hakko Bio

Find a price of Fostriecin bulk offered by Kyowa Hakko Bio

Find a price of L-Cysteine Hydrochloride bulk offered by Kyowa Hakko Bio

Find a price of L-Malic Acid bulk offered by Kyowa Hakko Bio

Find a price of Minocycline Hydrochloride bulk offered by Kyowa Hakko Bio

Find a price of Mitomycin bulk offered by Kyowa Hakko Bio

Find a price of Sodium Hyaluronate bulk offered by Kyowa Hakko Bio

Find a price of Taurine bulk offered by Kyowa Hakko Bio

Find a price of Ubidecarenone bulk offered by Kyowa Hakko Bio

Find a price of Uracil Mustard bulk offered by Kyowa Hakko Bio

Find a price of PEGYLATED GRANULOCYTE COLONY-STIMULATING FACTOR MUTEIN BULK SUBSTANCE bulk offered by Kyowa Hakko Bio

Find a price of L-ASPARAGINASE bulk offered by Kyowa Hakko Bio

Find a price of AMINO ACIDS--GENERAL INFO ON BULK DRUG SUBSTANCES bulk offered by Kyowa Hakko Bio

Find a price of L-GLUTATHIONE REDUCED (ORAL GRADE) bulk offered by Kyowa Hakko Bio

Find a price of MANUFACTURING SITE, FACILITIES, PERSONNEL, AND GENERAL OPERATING PROCEDURES IN ASHIKAGA-SHI, JAPAN. bulk offered by Kyowa Hakko Bio

Find a price of L-CYSTINE AND L-CYSTINE MONOHYDROCHLORIDE bulk offered by Kyowa Hakko Bio

Find a price of FACILITIES & CONTROLS (UBE PLANT IN JAPAN) bulk offered by Kyowa Hakko Bio

Find a price of FACILITIES AND PROCEDURES IN SHIZUOKA PREFECTURE, JAPAN bulk offered by Kyowa Hakko Bio

Find a price of Acetylcysteine bulk offered by Kyowa Hakko Bio

Find a price of L-Glutamic Acid bulk offered by Kyowa Hakko Bio

Find a price of Methionine bulk offered by Kyowa Hakko Bio

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty